NBSE Stock Overview
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NeuBase Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.42 |
| 52 Week High | US$4.80 |
| 52 Week Low | US$0.39 |
| Beta | 0.96 |
| 1 Month Change | -57.90% |
| 3 Month Change | -32.12% |
| 1 Year Change | -83.68% |
| 3 Year Change | -99.67% |
| 5 Year Change | n/a |
| Change since IPO | -99.54% |
Recent News & Updates
Recent updates
Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?
Aug 26
NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04
Aug 11NeuBase Therapeutics promotes Dr. William Mann to President and COO
Jun 29We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully
May 12Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?
Jan 24Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation
Oct 02Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation
Jun 02Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?
Feb 23We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth
Jan 19NeuBase Therapeutics EPS in-line
Dec 23NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy
Dec 16Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?
Dec 15Shareholder Returns
| NBSE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.3% | 1.5% | 1.2% |
| 1Y | -83.7% | 1.1% | 24.7% |
Return vs Industry: NBSE underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: NBSE underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| NBSE volatility | |
|---|---|
| NBSE Average Weekly Movement | 19.0% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NBSE's share price has been volatile over the past 3 months.
Volatility Over Time: NBSE's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 37 | Todd Branning | www.neubasetherapeutics.com |
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington’s disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene.
NeuBase Therapeutics, Inc. Fundamentals Summary
| NBSE fundamental statistics | |
|---|---|
| Market cap | US$1.58m |
| Earnings (TTM) | -US$24.59m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs NBSE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NBSE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$24.59m |
| Earnings | -US$24.59m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.55 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NBSE perform over the long term?
See historical performance and comparison